Reading view
Tahoe-100M: Mapping drug-induced molecular phenotypes at single-cell resolution
rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model
Cell Death Discovery, Published online: 16 September 2026; doi:10.1038/s41420-026-03345-y
rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse modelBroadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8
In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with HIV undergoing analytical treatment interruption, and initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound.The intrinsic cardiac nervous system is essential for cardiac function and survival
Anonymization of Portuguese Clinical Notes Using Large Language Models and Quantum-Enhanced Hybrid Architectures: Comparative Evaluation Study
Reproducing and Evaluating the Generalizability of Subliminal Learning in Open-Weight Models
4D Parallelism Unlocks Exascale Bayesian Neural Networks for High-Fidelity Atmospheric Modeling
PACE: A Neuro-Symbolic Framework for Plausible and Actionable Counterfactual Explanations
The Vienna 4G/5G Drive-Test Dataset
ETHOS: Towards a Modular Ethics Framework for Clinical Multi-Agent Systems
Donor-funded science is rising in Brazil ― upending a long tradition
Nature, Published online: 14 September 2026; doi:10.1038/d41586-026-02829-2
Philanthropists are stepping up support for research in a country where scientists have relied on the government alone for funding.Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial
Nature Cancer, Published online: 14 September 2026; doi:10.1038/s43018-026-01237-9
Marsoni et al. evaluated the feasibility of a dynamic circulating tumor DNA-guided adjuvant and postadjuvant treatment strategy in patients with resected microsatellite-stable, high-risk stage II or III colon cancer in the phase 2 PEGASUS trial.HAT1 regulates glioblastoma cell proliferation and membrane lipid remodeling through ALDH2
Cell Death Discovery, Published online: 14 September 2026; doi:10.1038/s41420-026-03328-z
HAT1 regulates glioblastoma cell proliferation and membrane lipid remodeling through ALDH2The 9 buzziest startups from Y Combinator’s latest Demo Day, according to VCs
Biomimetic cells for studying T cell mechanotransduction
Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03312-z
Biomimetic cells for studying T cell mechanotransductionAI-guided design of complete bacteriophage genomes
Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03311-0
AI-guided design of complete bacteriophage genomesOn-demand glycemic control by engineered bacteria
Nature Biotechnology, Published online: 10 September 2026; doi:10.1038/s41587-026-03323-w
On-demand glycemic control by engineered bacteriaClinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
Nature Medicine, Published online: 13 September 2026; doi:10.1038/s41591-026-04488-2
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.The effect of unique molecular identifier family size using tumor-informed circulating tumor-DNA analysis in childhood cancers
J Mol Diagn. 2026 Sep 11:S1525-1578(26)00156-X. doi: 10.1016/j.jmoldx.2026.08.002. Online ahead of print.
ABSTRACT
Analysis of circulating tumor-DNA (ctDNA) provides a molecular assessment that can complement routine imaging in childhood cancer management. Detailed monitoring of ctDNA levels may provide information on treatment efficacy and resistance, minimal residual disease and allows for early detection of relapse. Here, tumor-informed ctDNA analysis was applied to 90 blood plasma samples collected from eight children with malignant tumors. Four to ten tumor-specific mutations per patient were assessed using SiMSen-Seq, a digital sequencing approach utilizing unique molecular identifiers (UMIs). The effects of individual SiMSen-Seq assays and plasma samples were evaluated in relation to their impact on background error rate, number of detected target molecules and mutant calling using different UMI family size cutoff settings. The use of at least two sequencing reads per UMI provided the best overall performance by generating the highest number of detected target molecules and hence the optimal chance to detect low-frequent mutations. Data were consistent between SiMSen-Seq assays and plasma samples, providing robust ctDNA profiling over time for all patients. In conclusion, the results show that optimal use of UMIs in tumor-informed ctDNA analysis enables sensitive molecular readout that can assist in management of childhood cancers.
PMID:42727690 | DOI:10.1016/j.jmoldx.2026.08.002